AG
PBYI icon

Algert Global’s Puma Biotechnology PBYI Stock Holding History

Algert Global’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-48,178
Closed -$137K – 1296
2022
Q2 		$137K Buy
48,178
+6,290
+15% +$15.6K 0.01% 1076
2022
Q1 		$121K Buy
41,888
+14,430
+53% +$37.3K 0.01% 1093
2021
Q4 		$83K Buy
27,458
+8,870
+48% +$38.5K 0.01% 925
2021
Q3 		$130K Buy
+18,588
New +$139K 0.02% 955

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Algert Global's PBYI Position: Q3 2022 in Review

Algert Global sold out of Puma Biotechnology (PBYI) in Q3 2022, closing a stake of 48,178 shares — an estimated $137K sold.

Algert Global first reported a position in PBYI in Q3 2021 and held it in 4 quarters. The position peaked at $137K in Q2 2022. 83 funds tracked by Wall St. Rank hold PBYI as of Q3 2022.

  • Algert Global reported no remaining Puma Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Algert Global sold 48,178 Puma Biotechnology shares in Q3 2022, an estimated $137K.
  • Algert Global first reported a position in Puma Biotechnology in Q3 2021 and held it in 4 quarters.
  • Algert Global's Puma Biotechnology position peaked at $137K in Q2 2022.
  • 83 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2022.

Based on Algert Global's 13F filing for Q3 2022, filed 15 Nov 2022.